Up to £4,200 off tuition for international (non-UK and ROI) starting this September. No separate application. This short course will provide students with a critical understanding of stem cell biology ...

SINGAPORE – Local biotech firm Mirxes has refiled its draft prospectus for an initial public ... It planned to go public in late 2023 after its first filing in July 2023 but postponed the ...

The biotechnology firm ... According to the latest prospectus, the company’s revenue grew 36.2 per cent year on year to US$24.2 million in 2023, while it made a net loss of US$69.6 million ...

Sujal Patel: And Matt. Just to add just a tiny bit of additional sort of information for you on the cash side. So the cash guidance of having a cash runway into the second half of 2026, of course ...

SEATTLE, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology ... for the fourth quarter and fiscal year ended December 31, 2023. “2023 was a year of significant accomplishment and ...

VANCOUVER, British Columbia, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today ...

Joe Pantginis : Hi, good morning, everybody. Thanks to taking my question. Two questions please. So, first for 0101, wanted to ask about currently what you have ready to go followed by your ...

– Jennifer Towne, Ph.D., appointed as Executive Vice President and Chief Scientific Officer, effective November 6, 2023 – – Secured new BARDA funding for the development of RNA-delivered monoclonal ...

Nature Biotechnology’s annual survey highlights academic startups that are, among other things, correcting misfolded or disordered proteins, creating second generation GPCR agonists, building a ...

Sana Biotechnology, Inc SEATTLE, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today ...

SEATTLE--(BUSINESS WIRE)--AVM Biotechnology has been selected as a 2023-2024 National Cancer Institute (NCI) showcase company for the SBIR Investor Initiatives. Selection is based on competitive ...